DE60140270D1 - Lactamverbindungen und deren medizinische verwendung - Google Patents

Lactamverbindungen und deren medizinische verwendung

Info

Publication number
DE60140270D1
DE60140270D1 DE60140270T DE60140270T DE60140270D1 DE 60140270 D1 DE60140270 D1 DE 60140270D1 DE 60140270 T DE60140270 T DE 60140270T DE 60140270 T DE60140270 T DE 60140270T DE 60140270 D1 DE60140270 D1 DE 60140270D1
Authority
DE
Germany
Prior art keywords
diabetic
medical use
lactam compounds
agent
adiposis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140270T
Other languages
German (de)
English (en)
Inventor
Y Iino
T Ikenoue
N Kondo
H Matsueda
T Hatanaka
R Hirama
Y Masuzawa
F Ohta
A Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE60140270D1 publication Critical patent/DE60140270D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
DE60140270T 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung Expired - Lifetime DE60140270D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
DE60140270D1 true DE60140270D1 (de) 2009-12-03

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140270T Expired - Lifetime DE60140270D1 (de) 2000-12-01 2001-11-29 Lactamverbindungen und deren medizinische verwendung

Country Status (26)

Country Link
US (3) US7153850B2 (https=)
EP (1) EP1346993B1 (https=)
JP (2) JP3826400B2 (https=)
KR (1) KR100826818B1 (https=)
CN (2) CN100577651C (https=)
AT (1) ATE446297T1 (https=)
AU (3) AU1850202A (https=)
BG (1) BG107857A (https=)
BR (1) BR0115852A (https=)
CA (1) CA2430124C (https=)
CZ (1) CZ20031520A3 (https=)
DE (1) DE60140270D1 (https=)
ES (1) ES2331299T3 (https=)
HU (1) HUP0400806A3 (https=)
IL (1) IL156158A0 (https=)
MX (1) MXPA03004876A (https=)
NO (1) NO325401B1 (https=)
NZ (1) NZ526164A (https=)
PL (1) PL362835A1 (https=)
RU (1) RU2287530C2 (https=)
SK (1) SK6582003A3 (https=)
TW (1) TWI241302B (https=)
UA (1) UA76969C2 (https=)
WO (1) WO2002044180A1 (https=)
YU (1) YU42603A (https=)
ZA (1) ZA200304100B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
NZ563131A (en) 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
JP7566338B2 (ja) * 2019-01-23 2024-10-15 ▲たん▼解生醫股分有限公司 グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ－ラクタム化合物またはその塩

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药

Also Published As

Publication number Publication date
YU42603A (sh) 2006-03-03
US7632830B2 (en) 2009-12-15
KR20030051893A (ko) 2003-06-25
ZA200304100B (en) 2004-08-22
EP1346993A4 (en) 2005-12-21
US7153850B2 (en) 2006-12-26
RU2287530C2 (ru) 2006-11-20
CA2430124A1 (en) 2002-06-06
JP2006213732A (ja) 2006-08-17
NO20032439L (no) 2003-07-18
BR0115852A (pt) 2003-12-23
HUP0400806A3 (en) 2007-11-28
AU2006241377A1 (en) 2006-12-14
BG107857A (bg) 2004-06-30
ES2331299T3 (es) 2009-12-29
WO2002044180A1 (en) 2002-06-06
NO325401B1 (no) 2008-04-21
HUP0400806A2 (hu) 2004-07-28
JPWO2002044180A1 (ja) 2004-04-02
ATE446297T1 (de) 2009-11-15
EP1346993B1 (en) 2009-10-21
US20080096862A1 (en) 2008-04-24
CN100577651C (zh) 2010-01-06
UA76969C2 (en) 2006-10-16
TWI241302B (en) 2005-10-11
CN1269818C (zh) 2006-08-16
NZ526164A (en) 2004-09-24
US20040048847A1 (en) 2004-03-11
CN1487940A (zh) 2004-04-07
US7326701B2 (en) 2008-02-05
AU2006241377B2 (en) 2009-01-08
IL156158A0 (en) 2003-12-23
JP4505753B2 (ja) 2010-07-21
SK6582003A3 (en) 2003-09-11
PL362835A1 (en) 2004-11-02
MXPA03004876A (es) 2004-01-27
JP3826400B2 (ja) 2006-09-27
CN1911915A (zh) 2007-02-14
CZ20031520A3 (cs) 2003-10-15
EP1346993A1 (en) 2003-09-24
CA2430124C (en) 2011-01-11
NO20032439D0 (no) 2003-05-28
KR100826818B1 (ko) 2008-05-02
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
AU1850202A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
DE60140270D1 (de) Lactamverbindungen und deren medizinische verwendung
NL300985I1 (en) mogamulizumab
DE60022226D1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DE69821633D1 (de) Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält
AU2001276689A1 (en) Novel remedies for cancer
WO2002067916A3 (de) Pharmazeutische salze
ATE438626T1 (de) 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
BR0014775B1 (pt) misturas antimicrobianas de 1,3-bis (hidroximetil) -5,5-dimetilidantoina e 1,2-benzisotiazolin-3-ona.
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
DE59910758D1 (de) Transdermales pflaster, enthaltend mindestens einen die blutfettwerte beeinflussenden wirkstoff
WO2001039723A3 (en) Triazospiro compounds having nociceptin receptor affinity
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
NO985571L (no) Legemiddel for autoimmunsykdommer
ATE456651T1 (de) Metalloprotease mit aggrecanase-aktivität
TW200509980A (en) Parasiticidal composition
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
ATE454151T1 (de) Arzneimittel für nicht-cardiogene diastolische dysfunktion
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
ATE260032T1 (de) Fungizide mischung
ATE285236T1 (de) Antivirale zusammensetzungen enthaltend yohimbin als therapeutischen wirkstoff
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof
IL160490A0 (en) Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections
WO2003083487A3 (en) Method of screening of compounds inducing a prolonged qt intervalon the electrocardiogram

Legal Events

Date Code Title Description
8364 No opposition during term of opposition